Skip to main content

Advertisement

SpringerLink
Log in

Second- and third-line treatments in non-small cell lung cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Slow but steady progress has been made in the treatment of advanced non-small cell lung cancer. For first-line therapy, multiple chemotherapy combination therapies can extend survival and improve quality of life. And recently, for the first time ever, a noncytotoxic agent, the antivascular endothelial growth factor antibody bevacizumab, has been shown to improve survival when added to chemotherapy. Striking improvements have also been made in second-line treatment. In August 2004, only one agent was US Food and Drug Administration (FDA) approved in this setting, docetaxel, but by the beginning of 2005, two more were available, pemetrexed and erlotinib. All three of these drugs can significantly benefit patients, with 1-year survival in excess of 30%. Choosing between the three agents can be challenging, and this review focuses on the toxicity differences and predictors of response that can help guide this decision. Docetaxel and pemetrexed, both traditional intravenous cytotoxins, are excellent options for patients who have shown some response to first-line chemotherapy, but at this time, no other means exist to determine likelihood of response. When choosing between the two, pemetrexed causes significantly less neutropenia than does docetaxel, at least on the standard every-3-week regimen. With erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, there are factors that can predict for response, including little or no smoking history, and adenocarcinoma histology. Therefore, patients who fit these characteristics are good candidates for secondline erlotinib. However, the relationship between response to erlotinib and improved survival remains unclear, and several laboratory analyses that may help further, such as evaluation of EGFR gene copy number, are still under development. Although erlotinib is the only FDA-approved option currently available for third-line therapy, many patients with good performance status may benefit from third-line therapy and beyond. In addition to the approved second-line options, other single-agent chemotherapies to consider for treatment beyond second-line are gemcitabine, irinotecan, and oral topotecan. Many new drugs, including bevacizumab, ZD6474 (AstraZeneca, Wilmington, DE), sorafenib, cetuximab, paclitaxel poliglumex, epothilones, and others, alone or in combination with traditional agents, are currently undergoing investigation and hold great promise.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Readin

  1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29.

    PubMed  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153–156.

    Article  PubMed  CAS  Google Scholar 

  3. Ettinger DS, Cox JD, Ginsberg RJ, et al.: NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996, 10:81–111.

    CAS  Google Scholar 

  4. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996, 14:671–679.

  5. Kelly K, Crowley J, Bunn PA Jr, et al.: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210–3218.

    PubMed  CAS  Google Scholar 

  6. Schiller JH, Harrington D, Belani CP, et al.: Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002, 346:92–98.

    Article  PubMed  CAS  Google Scholar 

  7. Fossella F, Pereira JR, von Pawel J, et al.: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016–3024.

    Article  PubMed  CAS  Google Scholar 

  8. Sandler A, Gray R, Brahmer JR, et al.: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial--E4599 [abstract #LBA4]. J Clin Oncol 2005, 23:2s.

    Google Scholar 

  9. Shepherd FA, Dancey J, Ramlau R, et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095–2103. One of two pivotal trials establishing the role of docetaxel in the second-line therapy of advanced NSCLC. Primary study to show the benefit of second-line therapy versus best supportive care.

    PubMed  CAS  Google Scholar 

  10. Fossella FV, DeVore R, Kerr RN, et al.: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354–2362. One of two pivotal trials establishing the role of docetaxel in the second-line therapy of advanced NSCLC.

    PubMed  CAS  Google Scholar 

  11. Hanna N, Shepherd FA, Fossella FV, et al.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589–1597. Pivotal trial establishing the efficacy of pemetrexed in the second-line therapy of advanced NSCLC.

    Article  PubMed  CAS  Google Scholar 

  12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123–132. Pivotal trial that established the role of erlotinib for the second-line or third-line treatment of advanced NSCLC.

    Article  PubMed  CAS  Google Scholar 

  13. Dancey J, Shepherd FA, Gralla RJ, Kim YS: Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004, 43:183–194. This publication highlights the QoL benefits from second-line chemotherapy compared with BSC.

    Article  PubMed  Google Scholar 

  14. Camps C, Massuti B, Jimenez AM, et al.: Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) phase III trial [abstract 2514]. Proc Am Soc Clin Oncol 2003, 22:625.

    Google Scholar 

  15. Gridelli C, Gallo C, Di Maio M, et al.: A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004, 91:1996–2004.

    Article  PubMed  CAS  Google Scholar 

  16. Schuette W, Nagel S, Serke M, et al.: Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: results of a randomized phase III study [abstract 7036]. J Clin Oncol 2004, 22:625s.

    Google Scholar 

  17. Synold T, Newman E, Lenz H-J, et al.: Prospective evaluation of docetaxel (D) pharmacokinetics (PK) and toxicity in patients with tumor-related hepatic dysfunction (HD) [abstract 643]. Proc Am Soc Clin Oncol 1999, 18:168a.

    Google Scholar 

  18. Engels FK, Ten Tije AJ, Baker SD, et al.: Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004, 75:448–454.

    Article  PubMed  CAS  Google Scholar 

  19. Eisenhauer EA, Vermorken JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998, 55:5–30.

    Article  PubMed  CAS  Google Scholar 

  20. Calvert H: Folate status and the safety profile of antifolates. Semin Oncol 2002, 29:3–7.

    Article  PubMed  CAS  Google Scholar 

  21. Bunn P, Paoletti P, Niyikiza C, et al.: Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite [abstract 300]. Proc Am Soc Clin Oncol 2001, 20:76a.

    Google Scholar 

  22. Scagliotti GV, Shin DM, Kindler HL, et al.: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003, 21:1556–1561.

    Article  PubMed  CAS  Google Scholar 

  23. Tsao MS, Sakurada A, Cutz JC, et al.: Erlotinib in lung cancer--molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133–144. This publication outlines the clinical and laboratory parameters that can help to predict response to erlotinib.

    Article  PubMed  CAS  Google Scholar 

  24. Fukuoka M, Yano S, Giaccone G, et al.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237–2246.

    Article  PubMed  CAS  Google Scholar 

  25. Kris MG, Natale RB, Herbst RS, et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149–2158.

    Article  PubMed  CAS  Google Scholar 

  26. Janne PA, Gurubhagavatula S, Yeap BY, et al.: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, “Iressa≓) on an expanded access study. Lung Cancer 2004, 44:221–230.

    Article  PubMed  Google Scholar 

  27. Miller VA, Kris MG, Shah N, et al.: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:1103–1109.

    Article  PubMed  CAS  Google Scholar 

  28. Hirsch FR, Gandara DR, McCoy J, et al.: Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126) [abstract 7030]. J Clin Oncol 2005, 23:628s.

    Google Scholar 

  29. Huisman C, Smit EF, Giaccone G, Postmus PE: Secondline chemotherapy in relapsing or refractory nonsmall-cell lung cancer: a review. J Clin Oncol 2000, 18:3722–3730.

    PubMed  CAS  Google Scholar 

  30. Crino L, Mosconi AM, Scagliotti G, et al.: Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1999, 17:2081–2085.

    PubMed  CAS  Google Scholar 

  31. Sanchez R, Esteban E, Palacio I, et al.: Activity of weekly irinotecan (CPT-11) in patients with advanced nonsmall cell lung cancer pretreated with platinum and taxanes. Invest New Drugs 2003, 21:459–463.

    Article  PubMed  CAS  Google Scholar 

  32. Georgoulias V, Kouroussis C, Agelidou A, et al.: Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 2004, 91:482–488.

    Article  PubMed  CAS  Google Scholar 

  33. Stewart DJ: Update on the role of topotecan in the treatment of non-small cell lung cancer. Oncologist 2004, 9(Suppl 6):43–52.

    Article  PubMed  CAS  Google Scholar 

  34. Ramlau R, Gervais R, Krzakowski M, et al.: Oral topotecan demonstrates clinical activity in relapsed nonsmall cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel [abstract 7017]. J Clin Oncol 2005, 23:625s.

    Google Scholar 

  35. Chen YM, Perng RP, Lin WC, et al.: Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 2002, 25:509–512.

    Article  PubMed  Google Scholar 

  36. Munoz A, Rubio I, Mane JM, et al.: Phase II study of docetaxel/vinorelbine in patients with non-small-celllung cancer previously treated with platinum-based chemotherapy. Clin Lung Cancer 2002, 4:168–173.

    Article  PubMed  CAS  Google Scholar 

  37. Popa IE, Stewart K, Smith FP, Rizvi NA: A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced non-small cell lung carcinoma. Cancer 2002, 95:1714–1719.

    Article  PubMed  CAS  Google Scholar 

  38. Font A, Sanchez JM, Taron M, et al.: Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 2003, 21:435–443.

    Article  PubMed  CAS  Google Scholar 

  39. Niho S, Kubota K, Goto K, et al.: Combination secondline chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Cancer Chemother Pharmacol 2003, 52:19–24.

    Article  PubMed  CAS  Google Scholar 

  40. Frasci G, Comella P, Thomas R, et al.: Biweekly docetaxelirinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study. Cancer Chemother Pharmacol 2004, 53:25–32.

    Article  PubMed  CAS  Google Scholar 

  41. Grossi F, Belvedere O, Rossetto C, et al.: Irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC): an Alpe Adria Thoracic Oncology Multidisciplinary Group phase II study (ATOM 007) [abstract 7363]. J Clin Oncol 2004, 22:706s.

    Article  Google Scholar 

  42. Keresztes RS, Socinski MA, Bonomi P, et al.: Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC) [abstract 7137]. J Clin Oncol 2004, 22:650s.

    Google Scholar 

  43. Matsui K, Hirashima T, Nitta T, et al.: A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer. Jpn J Clin Oncol 2005, 35:181–187.

    Article  PubMed  Google Scholar 

  44. Pectasides D, Pectasides M, Farmakis D, et al.: Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced nonsmall-cell lung cancer: a randomized phase II trial. Ann Oncol 2005, 16:294–299.

    Article  PubMed  CAS  Google Scholar 

  45. Kouroussis C, Mavroudis D, Kakolyris S, et al.: High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 2004, 44:363–368.

    Article  PubMed  Google Scholar 

  46. Gatzemeier U, Pluzanska A, Szczesna A, et al.: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract 7010]. J Clin Oncol 2004, 22:619s.

    Google Scholar 

  47. Herbst RS, Prager D, Hermann R, et al.: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892–5899.

    Article  PubMed  CAS  Google Scholar 

  48. Davies AM, Lara PN, Lau DH, et al.: Intermittent erlotinib in combination with docetaxel (DOC): phase I schedules designed to achieve pharmacodynamic separation [abstract 7038]. J Clin Oncol 2005, 23:630s.

    Google Scholar 

  49. Bonomi P, Paz-Ares L, Langer C, et al.: Xyotax vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): the Stellar 2 phase III study [abstract O-099]. Lung Cancer 2005, 49:S35.

    Article  Google Scholar 

  50. Østerlind K, Sanchez JM, Zatloukal P, et al.: Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer [abstract 7110]. J Clin Oncol 2005, 23:647s.

    Google Scholar 

  51. Vansteenkiste JF, Breton JL, Sandler A, et al.: A randomized phase II study of epothilone analog BMS-247-550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy [abstract 2519]. Proc Am Soc Clin Oncol 2003, 22:626.

    Google Scholar 

  52. Yee L, Lynch TJ, Villalona-Calero M, et al.: A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer [abstract 7127]. J Clin Oncol 2005, 23:652s.

    Google Scholar 

  53. Herbst RS, Johnson DH, Mininberg E, et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:2544–2555.

    Article  PubMed  CAS  Google Scholar 

  54. Heymach JV, Johnson BE, Rowbottom JA, et al.: A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel in patients with NSCLC [abstract 3023]. J Clin Oncol 2005, 23:197s.

    Google Scholar 

  55. Lilenbaum R, Bonomi P, Ansari R, et al.: A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): final results [abstract 7036]. J Clin Oncol 2005, 23:629s.

    Google Scholar 

  56. Kim ES, Mauer AM, Tran HT, et al.: A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report [abstract 2581]. Proc Am Soc Clin Oncol 2003, 22:642.

    Google Scholar 

  57. Govindan R, Crowley J, Schwartzbberg L, et al.: Phase II trial of bexarotene capsules in patients with nonsmall-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for stage IIIB/IV disease [abstract 7116]. J Clin Oncol 2005, 23:648s.

    Google Scholar 

  58. Dragnev KH, Petty WJ, Shah S, et al.: A phase I trial of erlotinib and bexarotene as a targeted combination therapy for aerodigestive tract cancers [abstract 7093]. J Clin Oncol 2005, 23:643s.

    Article  CAS  Google Scholar 

  59. Fanucchi MP, Fossella F, Fidias P, et al.: Bortezomib +/- docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase II study [abstract 7034]. J Clin Oncol 2005, 23:629s.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2231, 94305, Stanford, CA, USA

    Heather Wakelee MD

Authors
  1. Atul Kumar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heather Wakelee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, A., Wakelee, H. Second- and third-line treatments in non-small cell lung cancer. Curr. Treat. Options in Oncol. 7, 37–49 (2006). https://doi.org/10.1007/s11864-006-0030-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-006-0030-9

Keywords

Search

Navigation